Overview

Webcast ImageWebcast
T2 Biosystems 2018 Second Quarter Financial and Operational Results Conference Call  (Live)
08/02/18 at 4:30 p.m. ET
T2 Biosystems 2018 Second Quarter Financial and Operational Results Conference Call
Thursday, August 2, 2018 4:30 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar

Corporate Profile

T2 Biosystems, an emerging leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, improves patient care and reduces the cost of care by helping clinicians effectively treat patients faster than ever before. T2 Biosystems' products include the T2Dx Instrument, T2Candida Panel and T2Bacteria Panel and are powered by the proprietary T2 Magnetic Resonance (T2MR®) technology. T2 Biosystems has an active pipeline of future products, including detection of additional species and antibiotic resistance markers of sepsis pathogens and tests for Lyme disease. For more information, please visit www.t2biosystems.com.
Stock Quote
TTOO (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$6.66
Change (%) Stock is Down 0.25 (3.48%)
Volume336,186
Data as of 07/20/18 3:25 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent News
DateTitle 
07/20/18T2 Biosystems Announces 2018 Second Quarter Financial and Operational Results Release and Conference Call Date
LEXINGTON, Mass., July 20, 2018 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), an emerging leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, today announced that it will release its 2018 second quarter financial and operational results after the market closes on Thursday, August 2, 2018. In conjunction with the release, the Company will host a conference call with the investment community at 4:30 p.m. Easte... 
Printer Friendly Version
07/09/18T2 Biosystems Reports Granting of Inducement Awards
LEXINGTON, Mass., July 09, 2018 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), an emerging leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, announced today that on July 2, 2018 it issued inducement awards to three new employees. These awards were made under T2 Biosystems’ Inducement Award Plan (the "Inducement Plan"), which was adopted by the company’s Board of Directors on March 1, 2018 and provides fo... 
Printer Friendly Version
06/25/18T2 Biosystems Added to the Russell 3000® Index
LEXINGTON, Mass., June 25, 2018 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), an emerging leader in the development of innovative diagnostic products for critical unmet needs in healthcare, announced today that it has been added to the broad-market Russell 3000® Index. The addition occurred at the conclusion of trading on June 22, 2018 and is effective after the US market opens on June 25, 2018. Annual Russell US Indexes reconstitution captures the 4,000 largest US stocks as of May... 
Printer Friendly Version
06/13/18Late-Breaking Data and Clinician Reviews on Now FDA-cleared T2Bacteria Panel Underscore Sepsis Prevention Opportunities at ASM Microbe 2018
LEXINGTON, Mass., June 13, 2018 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), an emerging leader in the development of innovative diagnostic products for critical unmet needs in healthcare, announced today late-breaker posters and data presented at the American Society for Microbiology (ASM) Microbe conference on June 7-11 that demonstrate the T2Bacteria® Panel’s accuracy and speed, which may enable more rapid treatment of patients with bloodstream infections in order to prevent sepsi... 
Printer Friendly Version

More News

Investor Contact Information
Contact: ir@T2Biosystems.com
(781) 761-4646

Matthew Clawson, W2O Group 
mclawson@w2ogroup.com
(339) 370-8500

Data provided by Nasdaq. Minimum 15 minutes delayed.